Venmax Drugs & Pharmaceuticals Ltd
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
- Market Cap ₹ 28.9 Cr.
- Current Price ₹ 25.0
- High / Low ₹ 37.0 / 19.0
- Stock P/E 116
- Book Value ₹ 12.2
- Dividend Yield 0.00 %
- ROCE 2.96 %
- ROE 2.70 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 247 to 65.1 days.
Cons
- Promoter holding has decreased over last quarter: -1.34%
- Promoter holding is low: 13.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.43 | 1.93 | 0.26 | 0.00 | 0.15 | 0.47 | 0.17 | 0.00 | 0.00 | 0.00 | 0.81 | 8.02 | |
| 2.54 | 2.07 | 0.88 | 0.23 | 0.38 | 0.72 | 0.50 | 0.12 | 0.19 | 0.11 | 1.74 | 7.90 | |
| Operating Profit | -0.11 | -0.14 | -0.62 | -0.23 | -0.23 | -0.25 | -0.33 | -0.12 | -0.19 | -0.11 | -0.93 | 0.12 |
| OPM % | -4.53% | -7.25% | -238.46% | -153.33% | -53.19% | -194.12% | -114.81% | 1.50% | ||||
| 0.00 | 0.00 | -0.72 | 0.00 | 0.00 | 0.00 | 0.18 | 1.98 | 0.42 | 0.20 | 0.92 | 0.16 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Profit before tax | -0.11 | -0.14 | -1.34 | -0.24 | -0.24 | -0.26 | -0.16 | 1.85 | 0.22 | 0.08 | -0.02 | 0.28 |
| Tax % | -36.36% | 0.00% | 0.00% | 0.00% | 0.00% | 3.85% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 10.71% |
| -0.08 | -0.14 | -1.34 | -0.24 | -0.24 | -0.27 | -0.16 | 1.85 | 0.23 | 0.06 | -0.01 | 0.25 | |
| EPS in Rs | -0.15 | -0.27 | -2.56 | -0.46 | -0.46 | -0.52 | -0.31 | 3.53 | 0.44 | 0.11 | -0.02 | 0.22 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 116% |
| 3 Years: | % |
| TTM: | 890% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 29% |
| 3 Years: | 3% |
| TTM: | 108% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 11.58 |
| Reserves | -4.90 | -5.04 | -7.11 | -7.35 | -7.59 | -7.86 | -8.03 | -6.18 | -5.95 | -5.89 | -0.83 | 2.53 |
| 1.50 | 1.72 | 1.85 | 2.04 | 2.24 | 2.52 | 2.33 | 0.35 | 0.35 | 0.35 | 0.05 | 0.33 | |
| 1.85 | 0.68 | 0.16 | 0.14 | 0.44 | 0.56 | 0.76 | 0.80 | 0.57 | 0.38 | 0.71 | 1.76 | |
| Total Liabilities | 3.69 | 2.60 | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 5.17 | 16.20 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.04 | 0.04 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 3.68 | 2.59 | 0.14 | 0.07 | 0.22 | 0.36 | 0.21 | 0.13 | 0.14 | 0.01 | 5.13 | 16.16 | |
| Total Assets | 3.69 | 2.60 | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 5.17 | 16.20 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -0.19 | -1.06 | -0.26 | -0.05 | -0.28 | 0.26 | 1.91 | 0.00 | 0.00 | -2.29 | -11.00 | |
| 0.00 | 0.00 | 0.01 | 0.00 | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.10 | 0.22 | 1.02 | 0.26 | 0.16 | 0.28 | -0.19 | -1.98 | 0.00 | 0.00 | 4.77 | 9.74 | |
| Net Cash Flow | 0.00 | 0.03 | -0.03 | 0.00 | 0.00 | 0.00 | 0.07 | -0.07 | 0.00 | 0.00 | 2.48 | -1.26 |
| Free Cash Flow | -0.10 | -0.19 | -1.05 | -0.26 | -0.17 | -0.28 | 0.26 | 1.91 | 0.00 | 0.00 | -2.29 | -11.00 |
| CFO/OP | 127% | 136% | 171% | 113% | 22% | 112% | -79% | -1,592% | 0% | -18% | 246% | -9,142% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21.03 | 128.60 | 0.00 | 0.00 | 31.06 | 85.88 | 428.09 | 65.08 | ||||
| Inventory Days | 225.44 | 0.00 | 0.00 | 446.11 | 250.94 | 0.00 | 27.72 | 50.14 | ||||
| Days Payable | 251.51 | 1,257.22 | 456.25 | 291.08 | 84.23 | |||||||
| Cash Conversion Cycle | -5.04 | 128.60 | 0.00 | -811.11 | -174.25 | 85.88 | 164.73 | 30.99 | ||||
| Working Capital Days | -3.00 | 5.67 | -2,723.46 | -5,986.00 | -2,112.34 | -6,333.82 | 851.67 | 587.55 | ||||
| ROCE % | -6.01% | -7.45% | -52.63% | 5.29% | 2.96% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Block of Property, Plant and Equipment INR Lakhs |
|
|||||||||
| Inventory of Finished Goods (Value-based proxy for volume) INR |
||||||||||
| Number of Employees Count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Statement Of Deviation & Variation
15 May - Venmax Drugs reported no deviation in preferential issue proceeds for quarter/year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 May - Newspaper Advertisement of the Audited Financial results for the Quarter and Year ended March 31, 2026.
- Audited Financial Results For The Quarter And Year Ended March 31, 2026 14 May
-
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31, 2026
14 May - Venmax Drugs posted audited FY26 results; revenue Rs 818.53 lakh, profit Rs 24.82 lakh, unmodified audit opinion.
-
Board Meeting Intimation for Audited Standalone Financial Results Of The Company For The Quarter And Year Ended March 31, 2026.
6 May - Board meeting on May 14, 2026 to approve audited FY26 financial results; trading window closed till May 16.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) VDPL is focused on establishing chain of Medical Stores with a brand name Ananya Pharma under the Venmax Drugs & Pharma Ltd, with the backing support of Formulations plant (Suzichem Labs). Currently, it has established 3 Shops & planning to expand them to 50 numbers around Hyderabad.
b) The company is developing oncology products in R&D. It is planning to establish a manufacturing UNIT with cGMP facility at Pharma Cluster at Hyderabad, to meet the export demand.